Human Molecular Genetics, 2002, Vol. 11, No. 17 1911-1926
© 2002 Oxford University Press
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain
1Center for Aging, Genetics and Neurodegeneration, Massachusetts General Hospital, Charlestown, MA 02129-4404, USA, 2Fred Hutchinson Cancer Research Center, Seattle WA 98109, USA and 3Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada V5H 4H4.
Received March 12, 2002; Accepted June 24, 2002
Previous analyses of gene expression in a mouse model of Huntington's disease (R6/2) indicated that an N-terminal fragment of mutant huntingtin causes downregulation of striatal signaling genes and particularly those normally induced by cAMP and retinoic acid. The present study expands the regional and temporal scope of this previous work by assessing whether similar changes occur in other brain regions affected in Huntington's disease and other polyglutamine diseases and by discerning whether gene expression changes precede the appearance of disease signs. Oligonucleotide microarrays were employed to survey the expression of
11 000 mRNAs in the cerebral cortex, cerebellum and striatum of symptomatic R6/2 mice. The number and nature of gene expression changes were similar among these three regions, influenced as expected by regional differences in baseline gene expression. Time-course studies revealed that mRNA changes could only reliably be detected after 4 weeks of age, coincident with development of early pathologic and behavioral changes in these animals. In addition, we discovered that skeletal muscle is also a target of polyglutamine-related perturbations in gene expression, showing changes in mRNAs that are dysregulated in brain and also muscle-specific mRNAs. The complete dataset is available at www.neumetrix.info.
* To whom correspondence should be addressed at: Fred Hutchinson Cancer Research Center, D4-100, 1100 Fairview Ave N, Seattle, WA 98109, USA. Tel: +1 2066677955; Fax: +1 2066672917; Email: jolson{at}fhcrc.org
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
F. Giorgini, T. Moller, W. Kwan, D. Zwilling, J. L. Wacker, S. Hong, L.-C. L. Tsai, C. S. Cheah, R. Schwarcz, P. Guidetti, et al. Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment J. Biol. Chem., March 21, 2008; 283(12): 7390 - 7400. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Stack, A. Dedeoglu, K. M. Smith, K. Cormier, J. K. Kubilus, M. Bogdanov, W. R. Matson, L. Yang, B. G. Jenkins, R. Luthi-Carter, et al. Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice J. Neurosci., November 21, 2007; 27(47): 12908 - 12915. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Strand, Z. C. Baquet, A. K. Aragaki, P. Holmans, L. Yang, C. Cleren, M. F. Beal, L. Jones, C. Kooperberg, J. M. Olson, et al. Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration J. Neurosci., October 24, 2007; 27(43): 11758 - 11768. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Runne, A. Kuhn, E. J. Wild, W. Pratyaksha, M. Kristiansen, J. D. Isaacs, E. Regulier, M. Delorenzi, S. J. Tabrizi, and R. Luthi-Carter Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood PNAS, September 4, 2007; 104(36): 14424 - 14429. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kuhn, D. R. Goldstein, A. Hodges, A. D. Strand, T. Sengstag, C. Kooperberg, K. Becanovic, M. A. Pouladi, K. Sathasivam, J.-H. J. Cha, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage Hum. Mol. Genet., August 1, 2007; 16(15): 1845 - 1861. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zuccato, N. Belyaev, P. Conforti, L. Ooi, M. Tartari, E. Papadimou, M. MacDonald, E. Fossale, S. Zeitlin, N. Buckley, et al. Widespread Disruption of Repressor Element-1 Silencing Transcription Factor/Neuron-Restrictive Silencer Factor Occupancy at Its Target Genes in Huntington's Disease J. Neurosci., June 27, 2007; 27(26): 6972 - 6983. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sadri-Vakili, B. Bouzou, C. L. Benn, M.-O. Kim, P. Chawla, R. P. Overland, K. E. Glajch, E. Xia, Z. Qiu, S. M. Hersch, et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models Hum. Mol. Genet., June 1, 2007; 16(11): 1293 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Stack, S. J. Del Signore, R. Luthi-Carter, B. Y. Soh, D. R. Goldstein, S. Matson, S. Goodrich, A. L. Markey, K. Cormier, S. W. Hagerty, et al. Modulation of nucleosome dynamics in Huntington's disease Hum. Mol. Genet., May 15, 2007; 16(10): 1164 - 1175. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zourlidou, T. Gidalevitz, M. Kristiansen, C. Landles, B. Woodman, D. J. Wells, D. S. Latchman, J. de Belleroche, S. J. Tabrizi, R. I. Morimoto, et al. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation Hum. Mol. Genet., May 1, 2007; 16(9): 1078 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N.T. Strehlow, J. Z. Li, and R. M. Myers Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space Hum. Mol. Genet., February 15, 2007; 16(4): 391 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tagawa, S. Marubuchi, M.-L. Qi, Y. Enokido, T. Tamura, R. Inagaki, M. Murata, I. Kanazawa, E. E. Wanker, and H. Okazawa The Induction Levels of Heat Shock Protein 70 Differentiate the Vulnerabilities to Mutant Huntingtin among Neuronal Subtypes J. Neurosci., January 24, 2007; 27(4): 868 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rockabrand, N. Slepko, A. Pantalone, V. N. Nukala, A. Kazantsev, J. L. Marsh, P. G. Sullivan, J. S. Steffan, S. L. Sensi, and L. M. Thompson The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis Hum. Mol. Genet., January 1, 2007; 16(1): 61 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Cummings, A. J. Milnerwood, G. M. Dallerac, V. Waights, J. Y. Brown, S. C. Vatsavayai, M. C. Hirst, and K. P.S.J. Murphy Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of huntington's disease Hum. Mol. Genet., October 1, 2006; 15(19): 2856 - 2868. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takeshita, R. Fujinaga, C. Zhao, A. Yanai, and K. Shinoda Huntingtin-associated protein 1 (HAP1) interacts with androgen receptor (AR) and suppresses SBMA-mutant-AR-induced apoptosis Hum. Mol. Genet., August 1, 2006; 15(15): 2298 - 2312. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Milnerwood, D. M. Cummings, G. M. Dallerac, J. Y. Brown, S. C. Vatsavayai, M. C. Hirst, P. Rezaie, and K. P.S.J. Murphy Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease Hum. Mol. Genet., May 15, 2006; 15(10): 1690 - 1703. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hodges, A. D. Strand, A. K. Aragaki, A. Kuhn, T. Sengstag, G. Hughes, L. A. Elliston, C. Hartog, D. R. Goldstein, D. Thu, et al. Regional and cellular gene expression changes in human Huntington's disease brain Hum. Mol. Genet., March 15, 2006; 15(6): 965 - 977. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Benn, C. Landles, H. Li, A. D. Strand, B. Woodman, K. Sathasivam, S.-H. Li, S. Ghazi-Noori, E. Hockly, S. M.N.N. Faruque, et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease Hum. Mol. Genet., October 15, 2005; 14(20): 3065 - 3078. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Borovecki, L. Lovrecic, J. Zhou, H. Jeong, F. Then, H. D. Rosas, S. M. Hersch, P. Hogarth, B. Bouzou, R. V. Jensen, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease PNAS, August 2, 2005; 102(31): 11023 - 11028. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Strand, A. K. Aragaki, D. Shaw, T. Bird, J. Holton, C. Turner, S. J. Tapscott, S. J. Tabrizi, A. H. Schapira, C. Kooperberg, et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker Hum. Mol. Genet., July 1, 2005; 14(13): 1863 - 1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Mazarakis, A. Cybulska-Klosowicz, H. Grote, T. Pang, A. Van Dellen, M. Kossut, C. Blakemore, and A. J. Hannan Deficits in Experience-Dependent Cortical Plasticity and Sensory-Discrimination Learning in Presymptomatic Huntington's Disease Mice J. Neurosci., March 23, 2005; 25(12): 3059 - 3066. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zucker, R. Luthi-Carter, J. A. Kama, A. W. Dunah, E. A. Stern, J. H. Fox, D. G. Standaert, A. B. Young, and S. J. Augood Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1 Hum. Mol. Genet., January 15, 2005; 14(2): 179 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Morton, N. I. Wood, M. H. Hastings, C. Hurelbrink, R. A. Barker, and E. S. Maywood Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease J. Neurosci., January 5, 2005; 25(1): 157 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Li and X.-J. Li Huntington and its Role in Neuronal Degeneration Neuroscientist, October 1, 2004; 10(5): 467 - 475. [Abstract] [PDF] |
||||
![]() |
C. A. Colton, Q. Xu, J. R. Burke, S. Y. Bae, J. K. Wakefield, A. Nair, W. J. Strittmatter, and M. P. Vitek Disrupted Spermine Homeostasis: A Novel Mechanism in Polyglutamine-Mediated Aggregation and Cell Death J. Neurosci., August 11, 2004; 24(32): 7118 - 7127. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schilling, A. V. Savonenko, A. Klevytska, J. L. Morton, S. M. Tucker, M. Poirier, A. Gale, N. Chan, V. Gonzales, H. H. Slunt, et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice Hum. Mol. Genet., August 1, 2004; 13(15): 1599 - 1610. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Ruan, M. Lesort, M. E. MacDonald, and G. V.W. Johnson Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway Hum. Mol. Genet., April 1, 2004; 13(7): 669 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Spires, H. E. Grote, N. K. Varshney, P. M. Cordery, A. van Dellen, C. Blakemore, and A. J. Hannan Environmental Enrichment Rescues Protein Deficits in a Mouse Model of Huntington's Disease, Indicating a Possible Disease Mechanism J. Neurosci., March 3, 2004; 24(9): 2270 - 2276. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Sugars, R. Brown, L. J. Cook, J. Swartz, and D. C. Rubinsztein Decreased cAMP Response Element-mediated Transcription: AN EARLY EVENT IN EXON 1 AND FULL-LENGTH CELL MODELS OF HUNTINGTON'S DISEASE THAT CONTRIBUTES TO POLYGLUTAMINE PATHOGENESIS J. Biol. Chem., February 6, 2004; 279(6): 4988 - 4999. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Obrietan and K. R. Hoyt CRE-Mediated Transcription Is Increased in Huntington's Disease Transgenic Mice J. Neurosci., January 28, 2004; 24(4): 791 - 796. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ebralidze, Y. Wang, V. Petkova, K. Ebralidse, and R. P. Junghans RNA Leaching of Transcription Factors Disrupts Transcription in Myotonic Dystrophy Science, January 16, 2004; 303(5656): 383 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Ferrante, J. K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, K. Smith, N. W. Kowall, R. R. Ratan, R. Luthi-Carter, et al. Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice J. Neurosci., October 15, 2003; 23(28): 9418 - 9427. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Marcora, K. Gowan, and J. E. Lee Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2 PNAS, August 5, 2003; 100(16): 9578 - 9583. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okuda, H. Hattori, S. Takeuchi, J. Shimizu, H. Ueda, J. J. Palvimo, I. Kanazawa, H. Kawano, M. Nakagawa, and H. Okazawa PQBP-1 transgenic mice show a late-onset motor neuron disease-like phenotype Hum. Mol. Genet., April 1, 2003; 12(7): 711 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hockly, V. M. Richon, B. Woodman, D. L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P. A. S. Lowden, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease PNAS, February 18, 2003; 100(4): 2041 - 2046. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cepeda, R. S. Hurst, C. R. Calvert, E. Hernandez-Echeagaray, O. K. Nguyen, E. Jocoy, L. J. Christian, M. A. Ariano, and M. S. Levine Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease J. Neurosci., February 1, 2003; 23(3): 961 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Strand, J. M. Olson, and C. Kooperberg Estimating the statistical significance of gene expression changes observed with oligonucleotide arrays Hum. Mol. Genet., September 15, 2002; 11(19): 2207 - 2221. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Luthi-Carter, A. D. Strand, S. A. Hanson, C. Kooperberg, G. Schilling, A. R. La Spada, D. E. Merry, A. B. Young, C. A. Ross, D. R. Borchelt, et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects Hum. Mol. Genet., August 15, 2002; 11(17): 1927 - 1937. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Y.W. Chan, R. Luthi-Carter, A. Strand, S. M. Solano, S. A. Hanson, M. M. DeJohn, C. Kooperberg, K. O. Chase, M. DiFiglia, A. B. Young, et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease Hum. Mol. Genet., August 15, 2002; 11(17): 1939 - 1951. [Abstract] [Full Text] [PDF] |
||||





